Kidney Week

Abstract: FR-PO908

Is Age Just a Number? A Comparative Analysis of Glomerular Disease across Ages from the CureGN Network

Session Information

• Glomerular Diseases: Potpourri
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Vissing, Andrew, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Andrew Vissing, MD

• Wadhwani, Shikha, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Shikha Wadhwani, MD, MS, FASN

• Smith, Abigail R., Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Abigail R. Smith, PhD

• Lane, Jerome C., Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Jerome C. Lane, MD

• Ghossein, Cybele, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Cybele Ghossein, MD

• Krissberg, Jill, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Jill Krissberg, MD

Background

Currently, there is limited research that investigates the characteristics and outcomes of adolescents and young adults (AYA) living with glomerular disease (GD). Our study seeks to understand how this group fares compared to younger and older patients.

Methods

Cure Glomerulonephropathy (CureGN) network is a multicenter prospective cohort study of children and adults with biopsy-proven GD diagnosed by biopsy within 5 years prior to enrollment. For our study, patients were categorized into the following groups: pediatric (≤13 years of age), AYA (14 to 25 years of age), and adult (≥26 years of age). Demographics and baseline disease characteristics were collected at enrollment and compared across age groups.

Results

The study included 2,405 patients (588 pediatric, 443 AYA and 1,374 adult). The prevalence of GD varied by age with minimal change disease being the most common in pediatrics (47.6%), IgA nephropathy in AYA (39.1%), and membranous nephropathy in adults (33.8%). More pediatric patients had active disease at enrollment (77.2% vs 68.9% in AYA and 69.4% in adults) but were also more likely to have reached complete remission at some point prior to enrollment (49.7% vs 32.1% in AYA and 22.3% in adults). Adults exhibited the lowest eGFR at enrollment (68.7 ml/min/1.73m² vs 86.0 ml/min/1.73m² in AYA and 104.6 ml/min/1.73m² in pediatrics).

Conclusion

This study highlights that AYA with GD have unique clinical characteristics when compared to either pediatric or adult populations. Recognizing this can help guide treatment and management strategies. Ongoing analysis for this project will explore whether AYA with GD have renal outcomes that differ compared to their younger and older counterparts.